239 related articles for article (PubMed ID: 37324457)
21. RIPK2 as a promising druggable target for autoimmune diseases.
Zhao W; Leng RX; Ye DQ
Int Immunopharmacol; 2023 May; 118():110128. PubMed ID: 37023697
[TBL] [Abstract][Full Text] [Related]
22. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.
Suebsuwong C; Dai B; Pinkas DM; Duddupudi AL; Li L; Bufton JC; Schlicher L; Gyrd-Hansen M; Hu M; Bullock AN; Degterev A; Cuny GD
Eur J Med Chem; 2020 Aug; 200():112417. PubMed ID: 32505849
[TBL] [Abstract][Full Text] [Related]
23. Convergence of innate immunity and insulin resistance as evidenced by increased nucleotide oligomerization domain (NOD) expression and signaling in monocytes from patients with type 2 diabetes.
Shiny A; Regin B; Balachandar V; Gokulakrishnan K; Mohan V; Babu S; Balasubramanyam M
Cytokine; 2013 Nov; 64(2):564-70. PubMed ID: 24018334
[TBL] [Abstract][Full Text] [Related]
24. Receptor-interacting protein kinase 2 contributes to host innate immune responses against Fusobacterium nucleatum in macrophages and decidual stromal cells.
Park JY; Lee TS; Noh EJ; Jang AR; Ahn JH; Kim DY; Jung DH; Song EJ; Lee YJ; Lee YJ; Lee SK; Park JH
Am J Reprod Immunol; 2021 Jul; 86(1):e13403. PubMed ID: 33580557
[TBL] [Abstract][Full Text] [Related]
25. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling.
Hrdinka M; Schlicher L; Dai B; Pinkas DM; Bufton JC; Picaud S; Ward JA; Rogers C; Suebsuwong C; Nikhar S; Cuny GD; Huber KV; Filippakopoulos P; Bullock AN; Degterev A; Gyrd-Hansen M
EMBO J; 2018 Sep; 37(17):. PubMed ID: 30026309
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors.
Wu S; Xu L; Wang X; Yang Q; Wang J; He S; Zhang X
Bioorg Med Chem Lett; 2022 Nov; 75():128968. PubMed ID: 36058467
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease.
Lai Y; Wang X; Sun X; Wu S; Chen X; Yang C; Zhang W; Yu X; Tong Y; Ma F; Zheng H; Zhang X; He S
Biochem Pharmacol; 2023 Aug; 214():115647. PubMed ID: 37315817
[TBL] [Abstract][Full Text] [Related]
28. Role of nucleotide-binding oligomerization domain 1 (NOD1) in pericyte-mediated vascular inflammation.
Navarro R; Delgado-Wicke P; Nuñez-Prado N; Compte M; Blanco-Toribio A; Nuñez G; Álvarez-Vallina L; Sanz L
J Cell Mol Med; 2016 May; 20(5):980-6. PubMed ID: 26915562
[TBL] [Abstract][Full Text] [Related]
29. NLRC3-like 1 inhibits NOD1-RIPK2 pathway via targeting RIPK2.
Fang H; Wu XM; Hu YW; Song YJ; Zhang J; Chang MX
Dev Comp Immunol; 2020 Nov; 112():103769. PubMed ID: 32634524
[TBL] [Abstract][Full Text] [Related]
30. Protein Kinase-Mediated Decision Between the Life and Death.
Engin A
Adv Exp Med Biol; 2021; 1275():1-33. PubMed ID: 33539010
[TBL] [Abstract][Full Text] [Related]
31. Receptor-Interacting Protein Kinase-2 Inhibition by CYLD Impairs Antibacterial Immune Responses in Macrophages.
Wex K; Schmid U; Just S; Wang X; Wurm R; Naumann M; Schlüter D; Nishanth G
Front Immunol; 2015; 6():650. PubMed ID: 26834734
[TBL] [Abstract][Full Text] [Related]
32. NOD2 in zebrafish functions in antibacterial and also antiviral responses via NF-κB, and also MDA5, RIG-I and MAVS.
Zou PF; Chang MX; Li Y; Xue NN; Li JH; Chen SN; Nie P
Fish Shellfish Immunol; 2016 Aug; 55():173-85. PubMed ID: 27235368
[TBL] [Abstract][Full Text] [Related]
33. RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
Duggan BM; Cavallari JF; Foley KP; Barra NG; Schertzer JD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32473019
[TBL] [Abstract][Full Text] [Related]
34. Inductive expression of the NOD1 signalling pathway in chickens infected with Salmonella pullorum.
Tao Z; Zhu C; Song W; Xu W; Zhang S; Liu H; Li H
Br Poult Sci; 2017 Jun; 58(3):242-250. PubMed ID: 28084794
[TBL] [Abstract][Full Text] [Related]
35. Growth Regulated Oncogene-α Upregulates TNF-α and COX-2 and Activates NOD1/RIPK2 mediated-MAPK Pathway in Head and Neck Squamous Cell Carcinoma.
Chan LP; Tseng YP; Wang HC; Chien CY; Wu CW; Wang LF; Liang CH
J Cancer; 2023; 14(6):989-1000. PubMed ID: 37151389
[No Abstract] [Full Text] [Related]
36. Pathogen-mediated proteolysis of the cell death regulator RIPK1 and the host defense modulator RIPK2 in human aortic endothelial cells.
Madrigal AG; Barth K; Papadopoulos G; Genco CA
PLoS Pathog; 2012; 8(6):e1002723. PubMed ID: 22685397
[TBL] [Abstract][Full Text] [Related]
37. XIAP controls RIPK2 signaling by preventing its deposition in speck-like structures.
Ellwanger K; Briese S; Arnold C; Kienes I; Heim V; Nachbur U; Kufer TA
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31350258
[TBL] [Abstract][Full Text] [Related]
38. Nucleotide-Binding Oligomerization Domain 1 (NOD1) Positively Regulates Neuroinflammation during Japanese Encephalitis Virus Infection.
Chen Z; Zhao Z; Liu Y; Imran M; Rao J; Cai N; Ye J; Cao S
Microbiol Spectr; 2022 Jun; 10(3):e0258321. PubMed ID: 35638852
[TBL] [Abstract][Full Text] [Related]
39. Immune modulating effects of receptor interacting protein 2 (RIP2) in autoinflammation and immunity.
Hofmann SR; Girschick L; Stein R; Schulze F
Clin Immunol; 2021 Feb; 223():108648. PubMed ID: 33310070
[TBL] [Abstract][Full Text] [Related]
40. Identification of Novel Protein Kinase Receptor Type 2 Inhibitors Using Pharmacophore and Structure-Based Virtual Screening.
Cruz JV; Neto MFA; Silva LB; da S Ramos R; da S Costa J; Brasil DSB; Lobato CC; da Costa GV; Bittencourt JAHM; da Silva CHTP; Leite FHA; Santos CBR
Molecules; 2018 Feb; 23(2):. PubMed ID: 29463017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
